Merck KGaA Appoints New CEO
Stefan Oschmann will replace new Karl-Ludwig Kley as chairman of the executive board and CEO of Merck KGaA.
On Oct. 13, 2015, Merck announced that Karl-Ludwig Kley will retire after serving nine years as chairman of the executive board and CEO of Merck KGaA. His replacement will be Stefan Oschmann, who has been a member of the executive board of Merck KGaA since 2011.
Johannes Baillou, chairman of the board of partners at E. Merck KG said in a press release that Oschmann's "strategic foresight and strong leadership have turned Merck KGaA, Darmstadt, Germany, into a respected player in the pharma industry again" and said that he hopes that Oschmann's new assignment will help the company navigate the "fundamental scientific and digital changes" that have been occurring in the industry.
Prior to his assignment as CEO of Merck KGaA, Stefan Oschmann worked for more than 20 years for the pharmaceutical company MSD Merck Sharp & Dohme, which is known in the United States as Merck & Co. He is currently president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and vice-president of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Source: Merck KGaA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
